CompletedPHASE2, PHASE3NCT00260988

A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery

Studying Complication in hemodialysis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ottawa Hospital Research Institute
Principal Investigator
Marc Rodger, MD, MSc
OHRI
Intervention
Fragmin (dalteparin)(drug)
Enrollment
29 target
Eligibility
18 years · All sexes
Timeline
2003 – 2008

Study locations (2)

Collaborators

LEO Pharma

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00260988 on ClinicalTrials.gov

Other trials for Complication in hemodialysis

Additional recruiting or active studies for the same condition.

See all trials for Complication in hemodialysis →

← Back to all trials